Masatoshi Eto - Concepedia

Author

Masatoshi Eto

Also Known As

E Efremov M, E. Burton M, E.M. E, Eto M, Eto Masatoshi, Eto, M., Eto, Masatoshi, François Xavier Nouhaud, Japan RCC Trialist Collaborative Group (JRTCG) investigators, M ETO

740

Publications

10.5K

Citations

H-Index

191

Concepts

All Affiliations

Kyushu University Kumamoto University Harasanshin Hospital Yamaguchi University Hirosaki University

About

Masatoshi Eto is an author at Kyushu University specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	78	3K
2	Health Sciences	10	10	243
3	Engineering	2	2	41
4	Natural Sciences	2	2	58
5	Education	1	1	28

Masatoshi Eto

203

Publications

Citations

H-Index

Page 1

	Year	Citations
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, New England Journal of Medicine	2021	1.7K
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma Yoshihiro Komohara, Hasita Horlad, Koji Ohnishi, Cancer Science Renal PathologyImmunologyRenal InflammationPathologyCancer Biology	2011	265
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial Marine Gross‐Goupil, Tae‐Geon Kwon, Masatoshi Eto, Annals of Oncology	2018	252
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer, The Lancet Oncology Pembrolizumab Versus SunitinibUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2023	149
Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209 Hiroshi Kitamura, Tadashi Tsukamoto, Taro Shibata, Annals of Oncology Radical CystectomyUrologySurgical OncologyGenitourinary CancerMedicine	2014	134
Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression Masaki Shiota, Akira Yokomizo, Yasuhiro Tada, Oncogene Reductive StressUrologyCastration ResistanceOncogenic AgentProstate Cancer Cells	2009	132
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Robert J. Motzer, Camillo Porta, Masatoshi Eto, Journal of Clinical Oncology	2024	126
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape Yoshiko Takeuchi, Tokiyoshi Tanegashima, Eiichi Sato, Science Immunology	2021	124
Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision Hiroaki Matsumoto, Koji Shiraishi, Haruhito Azuma, International Journal of Urology	2020	111

Page 1